Eli Lilly's oral GLP-1 agonist orforglipron was more effective than Novo Nordisk's rival oral formulation of semaglutide in a head-to-head diabetes trial, but likely won't answer the question of which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results